Clinical Burden and Healthcare Resource Use Among Adults Living with Hemophilia A: An Observational Study
PwHA with concurrent bleeding/joint disorders had higher clinical burden compared with those without MRB or joint disorders. Treatment approaches to reduce bleeding episodes, and consequently joint damage, in PwHA may reduce clinical burden.
Authors
- Lu Ban (ORCID: https://orcid.org/0000-0001-9388-9141)
- Lisa Young (ORCID: https://orcid.org/0000-0001-7988-9161)
- Patrick F. Fogarty (ORCID: https://orcid.org/0000-0003-3146-6519)
- Yong Chen (ORCID: https://orcid.org/0009-0006-9094-7012)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Thermo Fisher Scientific (China) (CN)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1007/s40801-025-00516-8
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer